Compare FMNB & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMNB | PCRX |
|---|---|---|
| Founded | 1887 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 839.7M | 1.0B |
| IPO Year | 2010 | 2010 |
| Metric | FMNB | PCRX |
|---|---|---|
| Price | $14.39 | $23.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $15.00 | ★ $30.25 |
| AVG Volume (30 Days) | ★ 387.0K | 372.3K |
| Earning Date | 04-22-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.89% | N/A |
| EPS Growth | 18.85 | ★ 107.44 |
| EPS | ★ 0.36 | 0.07 |
| Revenue | $279,922,000.00 | ★ $541,533,000.00 |
| Revenue This Year | $52.63 | $6.78 |
| Revenue Next Year | $8.28 | $8.54 |
| P/E Ratio | ★ $39.58 | $324.43 |
| Revenue Growth | 3.89 | ★ 26.04 |
| 52 Week Low | $12.23 | $18.80 |
| 52 Week High | $15.50 | $27.64 |
| Indicator | FMNB | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.73 | 54.58 |
| Support Level | $13.71 | $21.87 |
| Resistance Level | $14.68 | $23.97 |
| Average True Range (ATR) | 0.24 | 0.74 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 72.56 | 74.38 |
Farmers National Banc Corp is a financial holding company based in the U.S. Along with its subsidiaries, it operates in the domestic banking, trust, retirement consulting, insurance, and financial management industries. The group offers a full range of commercial and retail banking services, including checking accounts, savings accounts, time deposit accounts, commercial, mortgage, and installment loans, safe deposit boxes, ATMs, internet banking, and other banking services. Additionally, it offers personal and corporate trust services in the areas of estate settlement, trust administration, employee benefit plans, and retirement services; insurance products, and other financial products and services. The group's reportable segments are Bank, which generates the maximum revenue, and Trust.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.